Valenta Pharm, a company, has received the conclusion of the Russian Ministry of Industry and Trade on compliance of its new Valenta Research & Production Facility with the standards and requirements of Good Manufacturing Practice (GMP).
Anna Arutyunova, Quality Director of Valenta Pharm JSC, commented:
“The conclusion on compliance of the drug manufacturer with GMP requirements is a very important official recognition and high appreciation of our work. Effective pharmaceutical quality system at Valenta Research & Production Facility is a key strategic goal of our company. The policy of Valenta Pharm JSC provides for continuous improvement in the area of quality, which is seen as a way to gain consumer confidence and enhance stability of the company. Our motto is “Quality Without Compromise” because, by investing in high-tech and cutting-edge production facility, we not just manufacture high-quality medicinal products and make significant contribution to the development of Russian pharmaceutical industry, but first of all we improve the standards of living and health of people.”
Research & Production Facility of Valenta Pharm is one of the largest high-tech manufacturing sites in Eastern Europe with a total area of 19 thousand square meters. Its planned production capacity is 2 billion tablets and capsules and 30 million ampoules a year.